Advertisement

Journal of Genetics

, 98:3 | Cite as

Genetic and expression changes in \(\hbox {TNF-}\upalpha \) as a risk factor for rheumatoid arthritis pathogenesis in northeast India

  • Somdatta Das
  • Chitralekha Baruah
  • Anjan Kumar Saikia
  • Diptika Tiwari
  • Sujoy BoseEmail author
Research Article
  • 11 Downloads

Abstract

Antitumour necrosis factor-alpha \((\hbox {TNF-}\upalpha )\) therapy is used as a clinical intervention for rheumatoid arthritis (RA) but differences exist in response to the treatment which makes the candidature of the screening of \(\hbox {TNF-}\upalpha \) alteration(s) at genetic and expression levels an important agenda prior to treatment. This study aims to determine the associative role of \(\hbox {TNF-}\upalpha \) –308G/A polymorphism and differential expression of \(\hbox {TNF-}\upalpha \) in the pathogenesis of RA. A case–control study where a total of 126 RA patients were enrolled based on ACR-EULAR (2010) criteria, along with 160 community matched age and sex controls over a period of three years. The differential expression level of \(\hbox {TNF-}\upalpha \) mRNA and protein level was studied and \(\hbox {TNF-}\upalpha \) –308G/A polymorphism was screened by T-ARMS PCR assay. All statistical analysis was performed using SPSS software. mRNA expression level of \(\hbox {TNF-}\upalpha \) was upregulated in RA cases (avg. \(15.85\pm 9.52\) fold) compared to control. \(\hbox {TNF-}\upalpha \) protein level was found to be higher in RA cases (\(28.62\pm 7.17\) pg/mL) compared to control (\(23.14\pm 6.91\) pg/mL). \(\hbox {TNF-}\upalpha \) –308 variant GA genotype was higher in RA (46.03%) than in control (25%). The presence of \(\hbox {TNF-}\upalpha \) –308 variant A allele was associated with increased risk of RA susceptibility (odds ratio \((\hbox {OR})=2.559\) at 95% confidence interval (CI), \(P < 0.001\)) but not severity (\(\hbox {OR}=1.617\) at 95% CI, \(P=0.571\)). The presence of –308 variant genotype was associated with a higher \(\hbox {TNF-}\upalpha \) mRNA and protein expression. The presence of \(\hbox {TNF-}\upalpha \) –308A allele is associated with increased risk of RA susceptibility and differential \(\hbox {TNF-}\upalpha \) expression, and has prognostic significance. Association of higher \(\hbox {TNF-}\upalpha \) pro-inflammatory cytokine levels with northeast Indian patients makes them suitable subjects for \(\hbox {anti-TNF-}\upalpha \) therapy.

Keywords

autoimmunity rheumatoid arthritis tumour necrosis factor proinflammatory cytokine genetics case–control study 

Notes

Acknowledgements

The authors would like to acknowledge the staff of Gauhati Medical College and Hospital, Guwahati, Assam, India for their support in sample collection during the study.

References

  1. Alamanos Y. and Drosos A. A. 2005 Epidemiology of adult rheumatoid arthritis. Autoimmun. Rev. 4, 130–136.CrossRefGoogle Scholar
  2. Bax M., Jurgen van H., Huizinga Tom W. J. and Toes Rene E. M. 2011 Genetics of rheumatoid arthritis: what have we learned? Immunogenetics 63, 459–466.CrossRefGoogle Scholar
  3. Brinkman B. M., Zuijdeest D., Kaijzel E. L., Breedveld F. C. and Verweij C. L. 1995 Relevance of the tumor necrosis factor alpha (TNF alpha)-308 promoter polymorphism in TNF alpha gene regulation. J. Inflamm. 46, 32–41.PubMedGoogle Scholar
  4. Cvetkovic J. T., Wallberg-Jonsson S., Stegmayr B., Rantapaa-Dahlqvist S. and Lefvert A. K. 2002 Susceptibility for and clinical manifestations of rheumatoid arthritis are associated with polymorphisms of the TNF-alpha, IL-1beta, and IL-1Ra genes. J. Rheumatol. 29, 212–219.PubMedGoogle Scholar
  5. Danis V. A., Millington M., Hyland V., Lawford R., Huang Q. and Grennan D. 1995 Increased frequency of the uncommon allele of tumour necrosis factor alpha gene polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Dis. Markers 12, 127–133.CrossRefGoogle Scholar
  6. Dhawan S. S. and Quyyumi A. A. 2008 Rheumatoid arthritis and cardiovascular disease. Curr. Atheroscler. Rep10, 128–133.CrossRefGoogle Scholar
  7. Edith O.-R., Vázquez-Del M. M., Luz R.-Q. S., Navarro-Hernández R. E., Rangel-Villalobos H., Martínez-Bonilla G. et al. 2008 Tumor necrosis factor \(\upalpha \)-308 and -238 polymorphisms in rheumatoid arthritis. Association with messenger RNA expression and sTNF-\(\upalpha \). J. Invest. Med. 56, 937–943.CrossRefGoogle Scholar
  8. Elahi M. M, Asotra K, Matata B. M. and Mastana S. S. 2009 Tumor necrosis factor alpha-308 gene locus promoter polymorphism: an analysis of association with health and disease. BBA Mol. Basis Dis1792, 163–172.CrossRefGoogle Scholar
  9. Feldmann M. and Maini R. N. 2001 Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned. Annu. Rev. Immunol. 19, 163–196.CrossRefGoogle Scholar
  10. Gambhir D., Lawrence A., Aggarwal A., Misra R., Mandal S. K. and Naik S. 2010 Association of tumor necrosis factor alpha and IL-10 promoter polymorphisms with rheumatoid arthritis in North Indian population. Rheumatol. Int30, 1211–1217.CrossRefGoogle Scholar
  11. Gheita T. A., Azkalany Ghada S., Gaber W. and Mohey A. 2015 Clinical significance of serum TNF\(\upalpha \) and -308 G/A promoter polymorphism in rheumatoid arthritis. Egypt. Rheumatol. 37, 49–54.CrossRefGoogle Scholar
  12. Hajeer A. H and Hutchinson I. V. 2000 TNF-alpha gene polymorphism: clinical and biological implications. Microsc. Res. Tech. 50, 216–228.CrossRefGoogle Scholar
  13. Hassan S. Z., Gheita T. A., Kenawy S. A., Fahim A. T., El-Sorougy I. M. and Abdou M. S. 2011 Oxidative stress in systemic lupus erythematosus and rheumatoid arthritis patients: relationship to disease manifestations and activity. Int. J. Rheum. Dis. 14, 325–331.CrossRefGoogle Scholar
  14. Jahid M., Rehan-Ul-Haq, Jha P. K., Chawla D., Avasthi R. and Ahmed R. S. 2017 Tumor necrosis factor-\(\upalpha \)-308 polymorphism in North Indian rheumatoid arthritis patients and association with mRNA and serum \(\text{ TNF- }\upalpha \). Clin. Rheumatol. 36, 2209–2216.CrossRefGoogle Scholar
  15. Krugten van M. V., Huizinga T. W. J., Kaijzel E. L., Zanelli E., Drossaers-Bakker E. W., van de Linde P. et al. 1999 Association of the TNF +489 polymorphism with susceptibility and radiographic damage in rheumatoid arthritis. Genes Immun. 1, 91–96.CrossRefGoogle Scholar
  16. Lacki J. K., Moser R., Korczowska I., Mackiewicz S. and Muller W. 2000 \(\text{ TNF- }\upalpha \) gene polymorphism does not affect the clinical and radiological outcome of rheumatoid arthritis. Rheumatol. Int4, 137–140.CrossRefGoogle Scholar
  17. Li F., Xie X., Chen J., Gao J. and Lu F. 2015 Association of \(\text{ TNF- }\upalpha \) gene polymorphisms with the risk of rheumatoid arthritis in Han Chinese population from Hunan. J. Central South Univ. 40, 945–954.Google Scholar
  18. Ma X. and Xu S. 2010 TNF inhibitor therapy for rheumatoid arthritis. Biomed. Rep1, 177–184.CrossRefGoogle Scholar
  19. MacGregor A. J., Snieder H., Rigby A. S., Koskenvuo M., Kaprio J., Aho K. et al. 2000 Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum. 43, 30–37.CrossRefGoogle Scholar
  20. Maury C. P., Liljeström M., Laiho K., Tiitinen S., Kaarela K. and Hurme M. 2003 Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis. Arthritis Rheum. 48, 3068–3076.CrossRefGoogle Scholar
  21. Menges T., König I. R., Hossain H., Little S., Tchatalbachev S. and Thierer F. et al. 2008 Sepsis syndrome and death in trauma patients are associated with variation in the gene encoding tumor necrosis factor. Crit. Care Med. 36, 1456–1462.CrossRefGoogle Scholar
  22. Messemaker T. C., Huizinga T. W. and Kurreeman F. 2015 Immunogenetics of rheumatoid arthritis: understanding functional implications. J. Autoimmun. 64, 74–81.CrossRefGoogle Scholar
  23. Mosaad Y. M., Abdelsalam A. and El-bassiony S. R. 2011 Association of tumour necrosis factor-alpha-308 G/A promoter polymorphism with susceptibility and disease profile of rheumatoid arthritis. Int. J. Immunogenet38, 427–433.CrossRefGoogle Scholar
  24. Murdaca G., Gulli R., Spano F., Lantieri F., Burlando M., Parodi A. et al. 2014 \(\text{ TNF- }\upalpha \) gene polymorphisms: association with disease susceptibility and response to \(\text{ anti-TNF- }\upalpha \) treatment in psoriatic arthritis. J. Invest. Dermatol. 134, 2503–2509.CrossRefGoogle Scholar
  25. Nemec P., Pavkova-Goldbergova M., Stouracova M., Vasku A., Soucek M. and Gatterova J. 2008 Polymorphism in the tumor necrosis factor-alpha gene promoter is associated with severity of rheumatoid arthritis in the Czech population. Clin. Rheumatol27, 59–65.CrossRefGoogle Scholar
  26. Raychaudhuri S. 2010 Recent advances in the genetics of rheumatoid arthritis. Curr. Opin. Rheumatol22, 109–118.CrossRefGoogle Scholar
  27. Robak T., Gladalska A. and Stepień H. 1998 The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis. Eur. Cytokine Netw9, 145–154.PubMedGoogle Scholar
  28. Teuffel O., Ethier M. C., Beyene J. and Sung L. 2010 Association between tumor necrosis factor-alpha promoter -308 A/G polymorphism and susceptibility to sepsis and sepsis mortality: a systematic review and meta-analysis. Crit. Care Med. 38, 276–282.CrossRefGoogle Scholar
  29. Wilson A. G., Symons J. A., McDowell T. L., McDevitt H. O. and Duff G. W. 1997 Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc. Natl. Acad. Sci. USA 94, 3195–3199.CrossRefGoogle Scholar
  30. Yen J. H., Chen C. J., Tsai W. C., Lin C. H., Ou T. T., Hu C. J. et al. 2003 Manganese superoxide dismutase and cytochrome P450 1A1 genes polymorphisms in rheumatoid arthritis in Taiwan. Hum. Immunol64, 366–373.CrossRefGoogle Scholar

Copyright information

© Indian Academy of Sciences 2019

Authors and Affiliations

  • Somdatta Das
    • 1
  • Chitralekha Baruah
    • 2
  • Anjan Kumar Saikia
    • 3
  • Diptika Tiwari
    • 1
  • Sujoy Bose
    • 4
    Email author
  1. 1.Department of Bioengineering and TechnologyGauhati UniversityGuwahatiIndia
  2. 2.Department of MedicineGauhati Medical College and HospitalGuwahatiIndia
  3. 3.Gauhati Neurological and Research CentreGuwahatiIndia
  4. 4.Department of BiotechnologyGauhati UniversityGuwahatiIndia

Personalised recommendations